Treatment-related AEs occurring in ≥10% of patients on study (n = 84)
| . | Any grade . | Grade 3 or 4 . |
|---|---|---|
| Nausea | 63 (75%) | 2 (2%) |
| Fatigue | 59 (70%) | 11 (13%) |
| Anorexia | 54 (64%) | 3 (4%) |
| Thrombocytopenia | 44 (52%) | 38 (45%) |
| Vomiting | 36 (43%) | 2 (2%) |
| Diarrhea | 27 (32%) | 4 (5%) |
| Weight loss | 27 (32%) | 1 (1%) |
| Anemia | 26 (31%) | 19 (23%) |
| Hyponatremia | 25 (30%) | 22 (26%) |
| Neutropenia | 23 (27%) | 19 (23%) |
| Dehydration | 22 (26%) | 4 (5%) |
| Blurred vision | 18 (21%) | — |
| Dysgeusia | 17 (20%) | — |
| Dyspnea | 11 (13%) | — |
| Leukopenia | 10 (12%) | 7 (8%) |
| Muscle weakness | 10 (12%) | 3 (4%) |
| Confusion | 10 (12%) | 2 (2%) |
| . | Any grade . | Grade 3 or 4 . |
|---|---|---|
| Nausea | 63 (75%) | 2 (2%) |
| Fatigue | 59 (70%) | 11 (13%) |
| Anorexia | 54 (64%) | 3 (4%) |
| Thrombocytopenia | 44 (52%) | 38 (45%) |
| Vomiting | 36 (43%) | 2 (2%) |
| Diarrhea | 27 (32%) | 4 (5%) |
| Weight loss | 27 (32%) | 1 (1%) |
| Anemia | 26 (31%) | 19 (23%) |
| Hyponatremia | 25 (30%) | 22 (26%) |
| Neutropenia | 23 (27%) | 19 (23%) |
| Dehydration | 22 (26%) | 4 (5%) |
| Blurred vision | 18 (21%) | — |
| Dysgeusia | 17 (20%) | — |
| Dyspnea | 11 (13%) | — |
| Leukopenia | 10 (12%) | 7 (8%) |
| Muscle weakness | 10 (12%) | 3 (4%) |
| Confusion | 10 (12%) | 2 (2%) |